BIOLASE (BIOL) – Research Analysts' Recent Ratings Updates
BIOLASE (BIOL) – Research Analysts' Recent Ratings Updates
BIOLASE (NASDAQ: BIOL) has recently received a number of price target changes and ratings updates:
生物酶納斯達克(Sequoia Capital：Biol)最近收到了一系列目標價變化和評級更新：
- 12/3/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
- 11/25/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
- 11/17/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
- 11/16/2022 – BIOLASE had its price target lowered by analysts at Ascendiant Capital Markets to $14.00.
- 11/16/2022 – BIOLASE had its price target lowered by analysts at Benchmark Co. to $7.00.
- 11/11/2022 – BIOLASE had its price target lowered by analysts at Maxim Group from $10.00 to $5.00.
- 11/9/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
- 11/1/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
- 10/24/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
- 10/16/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
- 10/8/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
- 2022年12月3日-BIOLASE現在由StockNews.com的分析師負責。他們對該股設定了“賣出”評級。
- 2022年11月25日-BIOLASE現在由StockNews.com的分析師負責。他們對該股設定了“賣出”評級。
- 2022年11月17日-BIOLASE現在由StockNews.com的分析師負責。他們對該股設定了“賣出”評級。
- 2022年11月16日-Ascaldiant Capital Markets的分析師將BIOLASE的目標價下調至14.00美元。
- 2022年11月16日-基準公司的分析師將BIOLASE的目標價下調至7.00美元。
- 2022年11月11日-Maxim Group的分析師將BIOLASE的目標價從10.00美元下調至5.00美元。
- 2022年11月9日-BIOLASE現在由StockNews.com的分析師負責。他們對該股設定了“賣出”評級。
- 2022年11月1日-BIOLASE現在由StockNews.com的分析師負責。他們對該股設定了“賣出”評級。
- 2022年10月24日-BIOLASE現在由StockNews.com的分析師負責。他們對該股設定了“賣出”評級。
- 2022年10月16日-BIOLASE現在由StockNews.com的分析師負責。他們對該股設定了“賣出”評級。
- 2022年10月8日-BIOLASE現在由StockNews.com的分析師負責。他們對該股設定了“賣出”評級。
BIOLASE Stock Down 4.8 %
Biolase股價下跌4.8%
Shares of NASDAQ:BIOL opened at $0.78 on Wednesday. The firm's 50 day moving average price is $1.80 and its 200 day moving average price is $3.39. The stock has a market cap of $5.59 million, a price-to-earnings ratio of -0.22 and a beta of 1.34. BIOLASE, Inc. has a fifty-two week low of $0.76 and a fifty-two week high of $13.83. The company has a quick ratio of 1.27, a current ratio of 2.46 and a debt-to-equity ratio of 0.92.
納斯達克：Biol的股價週三開盤報0.78美元。該公司的50日移動均線價格為1.80美元，200日移動均線價格為3.39美元。該股市值為559萬美元，市盈率為-0.22倍，貝塔係數為1.34。Biolase，Inc.的股價為0.76美元，為52周低點，52周高點為13.83美元。該公司的速動比率為1.27，流動比率為2.46，債務權益比率為0.92。
Institutional Trading of BIOLASE
BIOLASE的機構交易
Several hedge funds have recently added to or reduced their stakes in BIOL. Commonwealth Equity Services LLC raised its holdings in BIOLASE by 117.8% in the first quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company's stock valued at $35,000 after acquiring an additional 54,650 shares in the last quarter. Essex Investment Management Co. LLC increased its stake in BIOLASE by 2.5% in the first quarter. Essex Investment Management Co. LLC now owns 1,621,992 shares of the medical technology company's stock valued at $573,000 after purchasing an additional 39,281 shares during the last quarter. State Street Corp increased its stake in BIOLASE by 4.5% in the first quarter. State Street Corp now owns 436,076 shares of the medical technology company's stock valued at $154,000 after purchasing an additional 18,682 shares during the last quarter. Capital Wealth Alliance LLC purchased a new position in BIOLASE in the second quarter valued at approximately $51,000. Finally, Citadel Advisors LLC purchased a new position in BIOLASE in the second quarter valued at approximately $118,000. Institutional investors and hedge funds own 21.21% of the company's stock.
幾家對衝基金最近增持或減持了Biol的股份。英聯邦股票服務有限責任公司在第一季度增持了117.8%的BIOLASE股份。Federal Equity Services LLC現在擁有這家醫療技術公司101,046股股票，價值35,000美元，上個季度又購買了54,650股。埃塞克斯投資管理公司第一季度增持了2.5%的BIOLASE股份。Essex Investment Management Co.LLC現在持有這家醫療技術公司1,621,992股股票，價值573,000美元，上個季度又購買了39,281股。道富銀行第一季度增持了4.5%的BIOLASE股份。道富集團目前持有436,076股這家醫療技術公司的股票，價值154,000美元，此前該公司在上個季度又購買了18,682股。Capital Wealth Alliance LLC在第二季度購買了BIOLASE的一個新頭寸，價值約51,000美元。最後，Citadel Advisors LLC在第二季度購買了BIOLASE的一個新頭寸，價值約為118,000美元。機構投資者和對衝基金持有該公司21.21%的股票。
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.
Biolase公司與其子公司一起，在美國和國際上為牙科醫生及其患者開發、製造、營銷和銷售激光系統。它的牙科激光系統允許牙醫、牙周病醫生、牙髓醫生、口腔外科醫生和其他牙科專家執行一系列微創牙科手術，如美容、修復和複雜的外科應用。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
- Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
- Should The Bancorp Make Your Small-Cap Watchlist for 2023?
- 3 Consumer Cyclical Stocks With Good Momentum
- Could Pinduoduo Be the Best Chinese Stock to Own?
- 3 Big Box Retail Bets for the Holidays
- 免費獲取StockNews.com關於BIOLASE的研究報告(Biol)
- Ulta發佈美好的財年前景，但這隻股票現在是買入的嗎？
- Bancorp應該入選2023年小盤股觀察名單嗎？
- 3勢頭良好的消費週期股
- 拼多多可能是最值得持有的中國股票嗎？
- 節假日的三大零售賭注
Receive News & Ratings for BIOLASE Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE Inc and related companies with MarketBeat.com's FREE daily email newsletter.
接受BIOLASE Inc.日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BIOLASE Inc.和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。